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Abstract 
A multiple-unit formulation for time-dependent colonic release of insulin was obtained by coating 15 
insulin and sodium glycocholate immediate-release minitablets with: i) Methocel
® 
E50, a low-
viscosity hydroxypropyl methylcellulose (inner coating); ii) 5:1 w/w Eudragit
® 
NE/Explotab
® 
V17, 
a mixture of a neutral polymethacrylate with a pore-forming superdisintegrant (intermediate 
coating); iii) Aqoat
®
 AS, enteric-soluble hydroxypropyl methylcellulose acetate succinate (outer 
coating). Sodium glycocholate was added as a permeation enhancer while the inner, intermediate 20 
and outer coatings were aimed, respectively, at delaying the onset of release through 
swelling/erosion processes, extending the duration of the lag phase by slowing down water 
penetration into the underlying functional layer, and overcoming variable gastric residence time. In 
vitro studies showed that neither insulin nor sodium glycocholate were released from the three-layer 
system during 2 h of testing in 0.1 N HCl, while complete release of the protein and of the enhancer 25 
occurred in phosphate buffer, pH 6.8, after consistent lag phases. No significant changes were 
noticed in the release profiles following twelve-month storage at 4 °C. Oral administration of the 
novel formulation to diabetic rats elicited a peak in the plasma insulin concentrations after 6 h, 
which was associated with a sharp decrease in the glycemic levels. The relative bioavailability and 
pharmacological availability of such a formulation, as determined vs the uncoated tablets, were 2.2 30 
and 10.3, respectively. Based on these results, the three-layer system presented was considered a 
potentially interesting tool for oral colonic delivery of insulin and adjuvant compounds. 
 
Keywords 
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Introduction 
Colon delivery is under extensive investigation as a promising approach to improve the oral 
bioavailability of peptide and protein drugs [1-3]. Although the large bowel fails to be ideally suited 40 
for absorption, it may indeed offer a number of advantages over the small intestine, including 
prolonged transit time, low levels of peptidases and good responsiveness to permeation enhancers 
[4-6]. A swellable/erodible time-dependent colon delivery platform (Chronotopic™) based on low-
viscosity hydroxypropyl methylcellulose (HPMC) coating was demonstrated to provide the pursued 
in vitro and in vivo release of low molecular weight drugs [7,8]. Accordingly, this system was 45 
proposed for colonic release of insulin combined with selected adjuvants, such as a protease 
inhibitor and an absorption enhancer [9-11]. For this purpose, the influence of all the involved 
manufacturing steps on the protein integrity was explored, thereby ruling out the occurrence of any 
significant degradation during the preparation of the delivery system. More recently, the design of 
such a system, originally presented in single-unit configurations, was modified to give multiple-unit 50 
dosage forms on account of the improved consistency of gastrointestinal transit and drug absorption 
profiles [12]. The thickness of the HPMC layer required to provide in vivo lag phases of suitable 
duration would indeed clash with size requirements of multiple units [13]. Thus, in order to improve 
the relevant efficiency in delaying the drug release, HPMC-coated minitablet cores were further 
coated with a mixture of neutral polymethacrylate Eudragit
® 
NE and superdisintegrant sodium 55 
starch glycolate, the latter acting as a pore former [14-16]. Such a film was intended to slow down 
the penetration of water into the underlying HPMC coating. This would extend the delay time prior 
to drug release while preserving the typical pulsatile release pattern of the original delivery system. 
Two-layer formulations having inner 250 µm HPMC layer and outer 20-30 µm Eudragit
® 
NE film 
containing 20% (on the dry polymethacrylate) of sodium starch glycolate were shown in vitro to 60 
yield programmable lag phases followed by prompt release, which resulted in the desired in vivo 
behavior. Moreover, they were physically stable over a three-year period when stored under 
ambient conditions.  
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On the basis of such premises, the present work was undertaken to evaluate this novel multiple-unit 
formulation as a possible time-dependent colon delivery system for insulin and permeation 65 
enhancer sodium glycocholate. 
 
Materials and Methods 
Bovine insulin and streptozotocin were obtained from Sigma-Aldrich (St. Louis, Missouri, US). 
Hydroxypropyl methylcellulose (HPMC, Methocel
®
 E50) was obtained from Colorcon (Gallarate, 70 
Italy) and microcrystalline cellulose (Avicel
®
 PH200) from FMC (Brussels, Belgium). 
Hydroxypropyl methyl cellulose acetate succinate (HPMCAS, Aqoat
®
 AS LG, Shin-Etsu, Tokyo, 
Japan) and poly(ethylacrylate, methylmethacrylate) (2:1 monomer molar ratio) 30% aqueous 
dispersion (Eudragit
®
 NE 30 D, Evonik Röhm, Darmstadt, Germany) were kind gifts of Seppic 
(Milan, Italy) and Rofarma (Gaggiano, Italy), respectively. Magnesium stearate was purchased from 75 
Carlo Erba Reagenti (Milan, Italy), microcrystalline cellulose (Avicel
®
 PH200) from FMC 
(Brussels, Belgium), polyethylene glycol (PEG 400) from ACEF (Fiorenzuola D'Arda, Italy), 
sodium glycocholate (NaGly) from Tokyo Chemical Industry (Tokyo, Japan) and sodium starch 
glycolate (Explotab
®
 V17 and Explotab
®
 CLV) from JRS Italia (Castenedolo, Italy). 
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Preparation of minitablet cores 
Convex minitablet cores were prepared by processing 4.0% bovine insulin, 51.0% microcrystalline 
cellulose, 40% sodium glycocholate, 4.5% sodium starch glycolate and 0.5% magnesium stearate 
powder mixture by a rotary machine (AM-8S, Officine Ronchi, Milan, Italy; die 2.5 mm diameter, 3 
mm curvature radius). The cores were checked for weight (n=20), height (digital micrometer 85 
Absolute, Mitutoyo, Kawasaki, Japan; n=20), crushing strength (crushing tester TBH28, Erweka, 
Heusenstamm, Germany; n=10) and disintegration time (USP 38 disintegration apparatus DT3, 
Sotax, Basel, Switzerland; n=6). The weight, height, crushing strength and the disintegration time 
of minitablet cores were 12.0±0.4 mg, 2.2±0.1 mm, 42.3±9.9 N and <1 min, respectively. 
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Coating of minitablet cores 
Minitablets were first coated by a rotary fluid bed (GPCG 1.1, Glatt, Binzen, Germany) with an 
aqueous solution of Methocel
®
 E50 (8.0% w/V) and PEG 400 (0.8% w/V). The resulting HPMC-
coated insulin minitablets (one-layer) were then coated by a bottom-spray fluid bed with diluted 
(1:1) Eudragit
®
 NE 30 D containing 20% w/w (on dry polymer) of Explotab
®
 V17 as previously 95 
described [14,15]. The two-layer formulation was finally enteric coated with a hydro-alcoholic 
solution of Aqoat
®
 AS (6% w/w in 3:1 w/w ethanol:water) by a ventilated coating pan (GS, Osteria 
Grande, Italy) under the following operating conditions: 150 g batch size; 60 °C inlet air 
temperature; 32–34 °C product temperature; 0.75 and 0.50 bar nebulizing and pattern pressure, 
respectively; 8 g/min spray rate; 30 rpm rotating speed; 11-12 cm nozzle – product distance. The 100 
three-layer formulation was finally cured at 40°C in an oven for 30 min. The Methocel
®
 E50 /PEG 
400, Eudragit
®
 NE/Explotab
®
 V17 and Aqoat
®
 AS coating levels were determined by subtracting 
the weight of units obtained at each coating step from that of the starting units (n=20), i.e. 
minitablets, one-layer systems or two-layer systems, and expressed as mg of solid applied per cm
2
. 
The surface and cross-section of the coated units were analyzed by scanning electron microscopy 105 
(SEM, Sigma, Zeiss, Oberkochen, Germany; gold sputtering 10 nm). 
 
In vitro release studies 
In vitro release studies (n=6) were carried out by means of an adapted three-position disintegration 
testing apparatus. This was selected in order to overcome adhesion of the hydrated HPMC coating 110 
to the vessels of a paddle dissolution apparatus [17]. Each unit, either a minitablet or a coated 
system, was inserted into a basket-rack assembly so that only one of the 6 available tubes was filled. 
During the test, every basket-rack assembly moved at a rate of 31 cycles/min in a separate vessel 
containing 160 mL of appropriate medium. A reduced volume of fluid was used so that insulin and 
sodium glycocholate released from each single uncoated or coated minitablet could be assayed. 115 
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Sink conditions were maintained throughout the whole test. Non-gastroresistant units were tested in 
phosphate buffer, pH 6.8, while enteric-coated ones were tested in 0.1 N HCl for 2 h and then in the 
phosphate buffer. The medium temperature of was set at 37±1 °C. Fluid samples of 0.5 mL were 
withdrawn at scheduled time points, and bovine insulin and sodium glycocholate were assayed by 
RP-HPLC as previously described [10]. Quantitation of insulin and sodium glycocholate was 120 
carried out using four-point calibration curves (R
2
 >0.99). Asn
21
 desamido insulin (A21) was not 
detected throughout the test. The release study (n=3) of final three-layer systems stored in closed 
glass vials at 4 °C was repeated after 3 and 12 months. 
In vitro lag time was expressed as the time required for 10% drug release in phosphate buffer, pH 
6.8 (t10%). t10% was calculated by linear interpolation of the experimental data immediately before 125 
and after this release percentage. 
 
In vivo studies  
Male Sprague Dowley rats, fed ad libitum and handled in accordance with the provisions of the 
European Economic Community Council Directive 86/209 (recognized and adopted by the Italian 130 
Government with the approval decree D.M. No. 230/95-B) and the NIH publication No. 85-23, 
revised in 1985, were subcutaneously treated with 65 mg/kg of streptozotocin. Animals with 
glucose levels of 400-500 mg/dL were divided into 3 groups (6 animals/group) and each received, 
via oral administration, 1 uncoated minitablet (Group 1), 1 three-layer coated system (Group 2) or 
0.4 mg insulin in solution (Group 3). At scheduled time points, 100 µL of blood was collected from 135 
the tail vein and centrifuged. Plasma samples (10 µL) were diluted with 10 mM phosphate buffer, 
0.15 M NaCl, pH 7.2, and glucose concentration was estimated by Trinder Kit (Sigma-Aldrich, St. 
Louis, Missouri, US) using a calibration curve obtained from standard glucose solutions. Insulin 
was assayed in plasma by ELISA using a human insulin-specific ELISA kit (Sigma-Aldrich, St. 
Louis, Missouri, US). Plasma samples of 10 µL were diluted to 100 µL with phosphate buffered 140 
saline before analysis. 
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Glucose and insulin concentration data were processed by using Kinetica Software 
(ThermoScientific, Rodano, Italy). Pharmacological availability was calculated as the area above 
the glucose concentration vs time curve considering the initial glucose level as the baseline point 
(AAC0→50 h). The protein bioavailability was calculated as the area under the insulin concentration 145 
vs time curve (AUC0→50 h). The relative pharmacological availability (PArel) and relative 
bioavailability (BArel) of the three-layer system (S) vs the minitablet (M) were also calculated as 
follows [18]: 
PArel = [AACS] / [AACM] 
BArel = [AUCS] / [AUCM] 150 
In vivo lag time (tlag) was calculated from the insulin concentration vs time curve as the time to 5% 
of AUC0→50 h. 
 
Statistical analysis 
Statistical analysis of in vitro and in vivo data was performed by two-group two-tail unpaired t-155 
Student test accounting for heteroscedasticity. The differences were considered significant with p 
<0.05. 
 
Results and Discussion 
The three-layer system depicted in Figure 1 was designed to yield release of insulin into the colon 160 
according to a time-dependent approach [1]. Such an approach relies on the relative consistency of 
small intestinal transit time (SITT) of dosage forms, which was shown to poorly be affected by the 
characteristics of the administered units and by the fasted/fed state of the subjects [19,20]. Hence, 
time-dependent colon delivery systems are generally devised so as to maintain integrity during 
unpredictable gastric residence and then start a lag phase intended to cover the entire SITT before 165 
releasing their drug load. 
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According to this formulation strategy, minitablet cores containing the protein along with sodium 
glycocholate were coated with low-viscosity HPMC (inner erodible layer), Eudragit
® 
NE/Explotab
®
 
V17 (intermediate permeable layer) and HPMCAS (outer gastroresistant layer).The intermediate 
layer was intended to prolong the duration of the lag phase prior to the protein release as imparted 170 
by the underlying erodible layer. The outer film was meant to overcome unpredictable gastric 
residence that would hinder timely release of insulin into the colon. 
Sodium glycocholate was incorporated into the core as an absorption enhancer. According to 
previous studies, this "active" excipient was selected because of its compatibility with the protein in 
the solid state and was demonstrated to effectively promote insulin permeation through the 175 
intestinal epithelium [10,21]. Sodium glycocholate was also found to inhibit proteases, which would 
be beneficial to insulin stability [22-25]. The gastrointestinal tolerability was another important 
feature in the permeation enhancer selection, as it is a requisite for the development of safe oral 
pharmaceutical products [21,26]. In the case of insulin delivery, this would especially be critical in 
view of the chronic use of this drug. 180 
All spray-coating steps were accomplished without major technical problems. Coated units obtained 
at each step met pre-set requirements for weight variability (RSD <6%). The HPMC, Eudragit
® 
NE/Explotab
®
 V17 and HPMCAS coatings resulted in 30.6, 1.9 and 7.8 mg/cm
2
 of each polymer 
applied, respectively, which corresponded to nominal layer thicknesses of 250, 20 and 100 µm. 
SEM analysis performed on the cross-sectioned three-layer systems showed continuous overlapping 185 
layers also at the tablet edges (Figure 2). 
In vitro studies were performed to evaluate the effect of the HPMC and Eudragit
® 
NE/Explotab
®
 
V17 coats on the release of insulin and sodium glycocholate.  
The profiles reported in Figures 3a and 4a show that the protein and the adjuvant were rapidly 
released from the minitablet cores. The HPMC layer markedly delayed the onset of insulin and 190 
sodium glycocholate release, as pointed out by Figures 3b and 4b. The Eudragit
® 
NE/Explotab
®
 
V17 coating enhanced the delaying effect of the HPMC layer, resulting in almost two-fold duration 
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of the lag phase in the case of the protein (Figures 3c and 4c). The release of sodium glycocholate 
started generally earlier than that of insulin. This behavior could be ascribed to the greater solubility 
of sodium glycocholate, at least of 2 orders of magnitude, and its lower molecular weight, which 195 
may favor the relevant diffusion through the coatings during swelling. However, either a concurrent 
or slightly earlier release of the adjuvant might be suitable in vivo for enhancing permeation of the 
protein through the enteric mucosa [27-29]. The release rate of both compounds, and particularly of 
insulin, was decreased in the presence of the Eudragit
® 
NE/Explotab
®
 V17 film. 
The lag time values (t10%) of insulin and sodium glycocholate from each formulation, collected in 200 
Table I, were fairly reproducible.  
After 2 h of testing in the acidic fluid, HPMCAS-coated units did not release either the protein or 
the permeation enhancer (Figure 5). This result confirmed the proper deposition of the enteric-
soluble polymer onto the substrate and, according to compendial requirements, would reflect in the 
needed protection of the delivery system during gastric residence. On the other hand, the 205 
gastroresistant coating was proved not to significantly delay the onset or affect the rate of release of 
insulin and sodium glycocholate at pH 6.8, thus pointing out rapid dissolution of HPMCAS under 
intestinal testing conditions and no alteration in the performance of the functional underlying layers 
(Figure 5, Table I). 
The release profiles obtained after 3 and 12 months of storage of the three-layer system at 4 °C 210 
showed minor, non-significant differences in terms of release onset as compared with the 
formulations tested at t=0 (Figure 6, Table I). However, a decreased release rate was observed after 
12 months. In this respect, a more extensive investigation into the curing conditions could help 
understand and overcome possible ageing phenomena.  
Overall, the in vitro performance, and in particular the duration of the lag phase observed under 215 
simulated intestinal pH conditions, was deemed potentially suitable for colonic release according to 
in vivo results previously collected from analogous delivery systems [16]. 
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In vivo studies were comparatively performed by oral administration of the three-layer system, 
uncoated minitablet and insulin in solution to diabetic rats. Figures 7 and 8 report the insulin and 
glucose concentration profiles in the blood over time. 220 
When dosed as a solution, insulin did not elicit any decrease in glycemia and, in the bloodstream, 
only fluctuations in a relatively narrow range around its initial concentration were observed. The 
uncoated minitablets yielded a slight increase in the insulin blood levels. A negligible decrease in 
the glucose concentration was seen within 3 h from administration but the hyperglycemic levels 
were rapidly restored. In contrast, the three-layer system brought about a sharp rise in the insulin 225 
concentration and decrease in the glucose levels. Statistical analysis of insulin concentration vs. 
time profiles pointed out significant differences in the AUC0→50 h obtained from the three-layer 
formulation against both the uncoated minitablet and the solution. The bioavailability of insulin 
from the three-layer system, the uncoated minitablet and the solution was 98.1, 44.5 and 17.7 
µg*mL
-1
*h, respectively. Analogously, the AAC0→50 h from the glucose concentration vs. time 230 
profiles of the three-layer system was significantly greater as compared with the uncoated 
minitablet and the solution. The relative insulin bioavailability (BArel) of the three-layer system, 
obtained as the AUC0→50 h ratio vs the uncoated minitablet, was 2.2, while the relative 
pharmacological availability (PArel), calculated as the AAC0→50 h ratio between the two 
formulations, was 10.3. 235 
The maximal protein concentration (Cmax 3.9 ng/mL) and glycemia reduction (about 70%) were 
obtained after 6 h from administration. Between 5 h and 50 h post-dose, the concentrations of 
insulin provided by the three-layer system were markedly higher than those detected with the 
uncoated minitablet and the solution. Lag time, expressed as the time to 5% of AUC0→50h, was of 
approximately 5 h. As expected based on previous data, the system was proved to delay the 240 
appearance of insulin in the bloodstream for a considerably more extended period of time with 
respect to the in vitro lag phase [15,16]. Besides, the rate of protein release into the gastrointestinal 
tract was such as to yield a prompt pharmacodynamic response at the end of lag time.  
 11 
Overall, the above-discussed results indicate that, when administering the proposed three-layer 
system, insulin would rapidly and effectively be absorbed after a lag phase. This delay may have 245 
allowed distal intestinal release and permeation of the protein. From literature data on 
gastrointestinal transit in rats, it could be inferred that insulin might have been absorbed while the 
delivery system was located in the ileo-colonic region [30-32]. Such findings seem to confirm that 
the terminal small bowel and large intestine would represent a viable peptide absorption site, at least 
with reference to the animal model in use. 250 
 
Conclusions 
An oral multiple-unit formulation for time-dependent colonic release of insulin was proposed. The 
system comprises an immediate-release minitablet core containing the protein and sodium 
glycocholate as a permeation enhancer, a swellable/erodible internal layer, a flexible and 255 
increasingly permeable intermediate film and an outermost enteric coating. 
The desired performance was obtained in vitro. The drug and the enhancer were not released during 
the acid stage of the test, and a prompt as well as complete liberation of both compounds occurred, 
after reproducible delay phases, under simulated intestinal pH conditions. Twelve-month storage at 
4 °C did not result in significant changes in the duration of lag phases. 260 
Administered to diabetic rats, the three-layer system described gave rise to a peak in plasma insulin 
concentration and a fall in the glucose level approximately 6 h after dosing. The bioavailability of 
the protein from the three-layer system was more than two-fold as compared with the relevant 
minitablet core, and pharmacological availability was ten-fold higher. 
Based on the outcome of this study, and on the potential scalability of the proposed delivery 265 
technology, the latter may represent a viable strategy to improve the oral bioavailability of a peptide 
drug. 
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Figure Captions 355 
Figure 1. Outline of the three-layer system: (a) drug-containing minitablet core; (b) HMPC layer; 
(c) Eudragit
®
 NE/Explotab
®
 V17 film; (d) enteric coating. 
 
Figure 2. SEM photomicrographs of a cross-sectioned three-layer system: (I) edge (magnification 
500x) and (II) side (magnification 1000x) views. (a) minitablet core; (b) HMPC layer; (c) Eudragit
®
 360 
NE/Explotab
®
 V17 film; (d) enteric coating. 
 
Figure 3. Individual release profiles of insulin from (a) uncoated minitablets, (b) HPMC-coated 
(one-layer) systems and (c) HPMC and Eudragit
®
 NE/Explotab
®
 V17-coated (two-layer) systems. 
 365 
Figure 4. Individual release profiles of sodium glycocholate from (a) uncoated minitablets, (b) 
HPMC-coated (one-layer) systems and (c) HPMC and Eudragit
®
 NE/Explotab
®
 V17-coated (two 
layer) systems. 
 
Figure 5. Individual release profiles of insulin and sodium glycocholate from three-layer systems in 370 
HCl 0.1 M and phosphate buffer, pH 6.8. 
 16 
 
Figure 6. Individual release profiles of insulin and sodium glycocholate from three-layer systems 
after (a) 3 months and (b) 12 months of storage at 4 °C. 
 375 
Figure 7. Plasma insulin concentration vs. time profiles in diabetic rats following oral 
administration of three-layer systems, uncoated minitablets or insulin in solution (bars indicate 
standard deviation). 
 
Figure 8. Plasma glucose concentration vs. time profiles in diabetic rats following oral 380 
administration of three-layer systems, uncoated minitablets or insulin in solution (bars indicate 
standard deviation). 
 
  
 17 
Table I. In vitro lag time of insulin and sodium glycocholate from the formulations under 385 
investigation. 
 
 t10% ± STD (min) 
Formulation Insulin 
Sodium 
glycocholate 
One-layer system 35.0 ± 1.9 28.7 ± 0.5 
Two-layer system 61.2 ± 2.7 45.4 ± 2.8 
Three-layer system 64.4 ± 6.9 52.0 ± 6.3 
Three-layer system (3 months) 73.7 ± 3.8 60.1 ± 2.5 
Three-layer system (12 months) 70.6 ± 7.0 57.3 ± 2.8 
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